ArticleFrontiers in immunology2026
400 AU/mL IgG protective threshold against SARS-CoV-2 XBB reinfection in Chinese inactivated vaccine recipients: implications for booster vaccination.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Data on antibody dynamics and protective threshold generated by infection with Omicron subvariants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), particularly among populations that have primarily (>90%) received inactivated coronavirus disease 2019 (COVID-19) vaccines, remain limited. Using data from two large-scale paired serosurveys, we analyzed real-world changes in SARS-CoV-2 antibody levels associated with specific hybrid immunity. Methods: The history of COVID-19 vaccination and SARS-CoV-2 infection were recorded for each participant. Serum samples collected at three-month intervals were analyzed for antibody levels against nucleocapsid (N) and spike (S) proteins using chemiluminescent microparticle immunoassay (CMIA). Linear mixed-effects model (LMM) and restricted cubic spline analysis were applied to assess antibody dynamics and determine protection thresholds, respectively. Results: A total of 4,065 participants were recruited in February and May 2023, with 2,894 completing both sampling rounds. Over three months, median IgG antibody levels declined by 28% (from 396.39 to 285.80 AU/mL). Prior infection and vaccination were significantly associated with higher antibody levels, while increasing age correlated with an annual decay of 0.38 AU/mL (most prominent in adults ≥60 years, 32.7% of whom fell below the protective threshold by follow-up). The IgG threshold for protection against XBB reinfection was 400 AU/mL, and each additional vaccination reduced reinfection risk by 13-15%. Conclusion: The 400 AU/mL IgG threshold provides a actionable quantitative guideline for prioritizing booster doses in Chinese adults aged ≥60 years (the fastest antibody decay subgroup) and high-risk groups. Routine antibody testing combined with this threshold could optimize targeted COVID-19 vaccination strategies in inactivated vaccine-predominant populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.